Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is well-positioned for continued success, with a strong portfolio of key products in the lucrative areas of cancer, cardiometabolic, and immunology. Management's commentary suggests strong sales growth and market expansion potential. Their implementation of sustainability considerations and focus on diversity, equity, and inclusion in clinical trials demonstrates a commitment to long-term success and responsible business practices.

Bears say

Eli Lilly is experiencing pricing pressure and lower-than-expected sales for its key products, leading to a decline in its stock performance compared to its peers. The company's ability to maintain its dominant position in the obesity market and sustain its revenue growth may be challenged by growing competition and regulatory pressures. Additional risks include potential pipeline setbacks, pricing pressures, and increased drug usage which could harm the company's margins and growth potential.

Eli Lilly (LLY) has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 20 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Sep 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,307.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,307.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.